Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05535764 · ClinicalTrials.gov registry record · Phase 1
Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis
A Phase 1 study of Myelofibrosis, sponsored by University of Utah.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05535764: Recruiting Phase 1 study of Myelofibrosis, sponsored by University of Utah.
NCT05535764 is a Phase 1 study of Myelofibrosis that is actively recruiting participants, run by University of Utah. The registered enrollment target is 18 participants, below the 196-participant average among 61 other Myelofibrosis trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05535764, a Phase 1 study of Myelofibrosis, is actively recruiting participants, sponsored by University of Utah.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single site, open-label, dose de-escalation, Phase 1 study of pegylated interferon alfa-2a administered after alloHCT in subjects with primary or secondary myelofibrosis. Part 1 of the study will assess the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period and identify the Recommended Phase 2 Dose (RP2D). Once the RP2D is identified, 6 additional patients will be enrolled in the expansion cohort.
Primary Outcome
To identify the Recommended Phase 2 Dose (RP2D) of pegylated interferon alfa-2a in subjects undergoing allogeneic hematopoietic cell transplantation for primary or secondary myelofibrosis
Conditions Studied
Interventions
- DRUG Pegylated interferon alpha2a
Study Locations (1)
Utah
- Huntsman Cancer Institute at the University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2023-08-02 |
| Est. Completion | 2027-10-30 |
| Phase | Phase 1 |
What NCT05535764 shows while recruiting
NCT05535764 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 196-participant average among 61 other Myelofibrosis trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which Pegylated interferon alpha2a is the first listed.
NCT05535764 reports a single indexed study location in Utah.
Frequently Asked Questions
What is clinical trial NCT05535764 about?
NCT05535764 is a clinical study titled "Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis". This is a single site, open-label, dose de-escalation, Phase 1 study of pegylated interferon alfa-2a administered after alloHCT in subjects with primary or secondary myelofibrosis. Part 1 of the study will assess the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period and identi...
What is the current status of trial NCT05535764?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2023-08-02. Estimated completion is 2027-10-30.
What conditions does trial NCT05535764 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT05535764?
The interventions under investigation include: Pegylated interferon alpha2a (DRUG).
Who is sponsoring clinical trial NCT05535764?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05535764 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05535764's enrollment target sits among peer trials
18 55th of 61 higher than 6 of 61 other Myelofibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myelofibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RECRUITING · Phase 1
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
-
Mutant CALR-peptide Based Vaccine in Patients With Mutated CALR Myeloproliferative Neoplasm
RECRUITING · Phase 1
-
Treating Anemia in Myelofibrosis With Repurposed Drugs (Nelfinavir) That Restore Iron Delivery to the Bone Marrow
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI